Form 4: AIM ImmunoTech Director Acquires Shares as Part of Cash Conservation Plan

Director Stewart Appelrouth acquired 24,452 shares of AIM ImmunoTech Inc. common stock on December 13, 2024, as part of the company's Cash Conservation Plan.

Summary

• Stewart Appelrouth, a director of AIM ImmunoTech Inc., acquired 24,452 shares of common stock on December 13, 2024.
• The shares were acquired at a price of $0.213 per share.
• This transaction increased Appelrouth's direct holdings to 379,961 shares.
• The shares were issued in lieu of director compensation under the company's Cash Conservation Plan.

Sentiment

Score: 7

Explanation: The transaction is a routine part of the company's compensation plan and shows director confidence, but it is not a major event.

Positives

• The acquisition of shares by a director demonstrates confidence in the company.
• The use of shares for compensation helps the company conserve cash.

Management Comments

• The shares were issued in lieu of director compensation pursuant to the issuer's Cash Conservation Plan.

Industry Context

This type of transaction is common in publicly traded companies, where directors may receive stock as part of their compensation, especially in companies focused on conserving cash.

Comparison to Industry Standards

• Many biotech companies use stock-based compensation to conserve cash, particularly during development phases.
• Director stock acquisitions are a common practice and are often seen as a positive sign of alignment between management and shareholder interests.
• The specific amount of shares and price are unique to AIM ImmunoTech and its compensation plan.

Stakeholder Impact

• Shareholders may view this as a positive sign of director alignment with company interests.
• The company conserves cash by issuing shares instead of cash compensation.

Key Dates

Keywords

AIM ImmunoTech, Director, Share Acquisition, Cash Conservation Plan, Stock Compensation, Beneficial Ownership